The Predictive Value of Serum sIL-2R Combined with TNF-α, IgG and IgA in the Recurrence of Multiple Myeloma.
10.19746/j.cnki.issn.1009-2137.2025.01.021
- Author:
Ping LIN
1
;
Ya-Lan ZHANG
1
;
Ruo-Teng XIE
1
;
Xue-Ya ZHANG
2
Author Information
1. Department of Laboratory Medicine,The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, Fujian Province, China.
2. Department of Hematology, The Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, Fujian Province, China.
- Publication Type:Journal Article
- Keywords:
soluble interleukin-2 receptor;
tumor necrosis factor alpha;
IgG;
IgA;
multiple myeloma;
recurrence
- MeSH:
Humans;
Multiple Myeloma/blood*;
Immunoglobulin A/blood*;
Immunoglobulin G/blood*;
Tumor Necrosis Factor-alpha/blood*;
Receptors, Interleukin-2/blood*;
Recurrence;
Male;
Female;
Neoplasm Recurrence, Local;
Middle Aged;
Prognosis
- From:
Journal of Experimental Hematology
2025;33(1):150-156
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVE:To investigate the predictive value of serum soluble interleukin-2 receptor(sIL-2R), tumor necrosis factor alpha(TNF-α), IgG and IgA for the recurrence in patients with multiple myeloma(MM).
METHODS:A total of 108 MM patients who were initially diagnosed and treated in our hospital from January 2017 to March 2019, and 72 patients who met the diagnostic criteria and had complete follow-up data were selected as the study subjects. MM recurrence was the endpoint event, and follow-up was conducted until the occurrence of the endpoint event or the deadline of this study. MM patients were divided into recurrent group(RG) and non-recurrent group(NRG) based on whether they have relapsed or not. Venous blood was collected from patients at the first diagnosis and follow-up (at the occurrence of endpoint events or termination of the study), and enzyme-linked immunosorbent assay(ELISA) was used to detect sIL-2R and TNF-α levels in the patient's serum. An automatic immune analyzer was used to detect the levels of IgG and IgA in the patient's serum. The differences in expression levels of the factors between two groups were compared and the correlations between sIL-2R and TNF-α, IgG and IgA at the first diagnosis and follow-up were analyzed. At the same time, venous blood was collected from patients during complete remission, and their serum sIL- 2R levels were measured to compare the differences in sIL-2R expression levels at the first diagnosis, complete remission and recurrence. Receiver operating characteristic(ROC) curves was used to determine the optimal cutoff values for serum sIL-2R, TNF-α, IgG and IgA, and the predictive value of sIL-2R, TNF-α, IgG and IgA in the recurrence of MM patients were analyzed based on the area under the curve(AUC).
RESULTS:The serum sIL-2R levels of MM patients at the first diagnosis and recurrence were significantly higher than at complete remission (P < 0.05). At the first diagnosis, the hemoglobin content of RG was lower than that of NRG, while the β2-microglobulin content was higher than that of NRG (P < 0.001). There was no significant difference in other clinical parameters between the two groups (P >0.05). The levels of sIL-2R, TNF-α, IgG and IgA at the first diagnosis and follow-up of RG were higher than those of NRG (P < 0.05). There was a significant correlation between sIL-2R and TNF-α, IgG and IgA at the first diagnosis and follow-up (P < 0.001). The ROC curve showed that, at the first diagnosis, sIL-2R, TNF-α, IgG and IgA predicted the AUC of MM patients were 0.919, 0.850, 0.766 and 0.795, respectively, after follow-up, they predicted AUC of MM were 0.890, 0.815, 0.760 and 0.794, respectively (P < 0.001).
CONCLUSION:The serum sIL-2R has the highest predictive value for MM patient's recurrence, and it is possible to detect the TNF-α, IgG and IgA levels at specific times to infer changes in sIL-2R levels and evaluate the patient's prognosis.
